www.robinspost.com


A joint study by University of East Anglia and University of Glasgow performs a meta-analysis of 167 experiments across eight vertebrate species, showing rapamycin reliably matches the life-extension benefits of intermittent fasting without requiring dietary restriction, highlighting its promise for further aging therapeutics.

Key points

  • Meta-analysis of 167 experiments across eight vertebrate species reveals rapamycin matches lifespan gains of intermittent fasting.
  • Rapamycin extends life in fish, rodents, and primates regardless of sex or feeding protocol, whereas metformin lacks consistent benefits.
  • Study employs systematic review methodology to benchmark rapamycin against calorie restriction, supporting its potential for human aging trials.

Why it matters: The study underscores drug repurposing potential for practical, less restrictive longevity interventions with significant implications for aging therapeutics.

Q&A

  • What is rapamycin?
  • How does dietary restriction extend lifespan?
  • What is a meta-analysis in this context?
  • Why did metformin show no lifespan benefit?
Copy link
Facebook X LinkedIn WhatsApp
Share post via...
Consumer News: Rapamycin found to match lifespan gains of fasting